Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

Recruiting now

Conditions studied: Prostate Cancer Metastatic

In brief

This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.

Key facts

Study ID

NCT06260410

Run by

Erasmus Medical Center

People needed

150

Starts

2024-02-20

Expected to finish

2027-02-01

Last updated by the study team

2024-04-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participants should be at least 18 years old.
• Participants should be able to understand the written information and be able to provide informed consent.
• Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.

You may not qualify if…

• None applicable

Where it is running

• Erasmus MC — Rotterdam, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.